InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,487.03
(
0.25%
)
US TECH 100
19,430.40
(
0.14%
)
Dow Jones
38,834.86
(
0.15%
)
Brent Oil
84.71
(
-0.09%
)
Bitcoin
65,494.74
(
0.55%
)
Post# of 252254
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 834
Posts 119875
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 89693

Thursday, 10/06/2011 6:48:01 PM

Thursday, October 06, 2011 6:48:01 PM

Post# of 252254
FDA approves Cialis for BPH:

http://www.reuters.com/article/2011/10/06/fda-cialis-idUSN1E7951ZG20111006

Cialis’ US CoM patent runs until Nov 2017, so there’s still plenty of time for LLY to benefit from the new indication. On the other hand, the BPH arena is crowded and includes drugs such as Proscar that are already off-patent. Perhaps LLY’s best bet is to position Cialis as the drug of choice for men who have both ED and BPH.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up